Chlorambucil-induced acute interstitial pneumonitis

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Chlorambucil is a standard alkylating agent for chronic lymphocytic leukemia (CLL).
• Pulmonary toxicity, specifically interstitial pneumonitis, is a rare but serious adverse effect associated with chlorambucil.
• This toxicity may manifest even after the cessation of chlorambucil therapy.

Purpose of the Study:

• To report a case of interstitial pneumonitis following chlorambucil treatment for CLL.
• To systematically review existing literature on chlorambucil-induced pulmonary toxicity.
• To raise awareness among clinicians regarding this potential adverse effect.

Main Methods:

• Case report of an 83-year-old male treated for CLL.
• Systematic literature review of case reports on chlorambucil-induced pulmonary toxicity.
• Analysis of identified cases for risk factors and clinical presentation.

Main Results:

• A case of interstitial pneumonitis developed 1.5 months post-chlorambucil treatment, responding to prednisone.
• A review identified 13 additional case reports of chlorambucil-induced interstitial pneumonitis.
• No common risk factors were identified, and the mechanism remains unclear.
• Major clinical trials have not frequently reported this adverse event, possibly due to underreporting.

Conclusions:

• Interstitial pneumonitis is a potential, albeit rare, adverse effect of chlorambucil therapy for CLL.
• Clinicians should consider drug-induced interstitial pneumonitis in the differential diagnosis of patients presenting with suggestive symptoms, even after chlorambucil discontinuation.
• Further investigation into the mechanism and risk factors for chlorambucil-induced pulmonary toxicity is warranted.